ArticleJournal of molecular cell biology2020
Protective effects of human umbilical cord mesenchymal stem cell-derived conditioned medium on ovarian damage.
Article in Journal of molecular cell biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 64 citations in OpenAlex.
- Granulocyte colony-stimulating factor priming improves embryos and pregnancy rate in patients with poor ovarian reserve: a randomized controlled trial.Reproductive biology and endocrinology : RB&E · 2023Trial
- Article
- Mesenchymal stem cell-based therapeutic strategies for female infertility: current evidence and emerging targeting approaches.Biotechnology letters · 2026Review
- Repair of female reproductive function by GDF-9-overexpressing extracellular vesicles via ACVR1B/SMAD2 regulation in ovarian granulosa.Science advances · 2025Article
- Ginsenoside Rg1 Alleviates Hydrogen Peroxide-Induced Autophagy and Apoptosis in Ovarian Granulosa Cells.Cell biochemistry and biophysics · 2025Article
- Transplantation of UC-MSCs in ovary improves ovarian function and intermediate outcomes in IVF/ICSI cycles of POI patients: a clinical cohort study.Stem cell research & therapy · 2025Article
- Precision medicine in premature ovarian insufficiency: a focus on the precision therapeutic strategies for mesenchymal stem cells.Stem cell research & therapy · 2025Review
- Ovarian Stromal Cell-Conditioned Media, but Not Co-Culture, Improves Survival in Feline Follicles.Animals : an open access journal from MDPI · 2025Article
- Extracellular Vesicles Present in Bone Marrow Mesenchymal Stromal/Stem Cell Conditioned Media Restore Spermatogenesis in Azoospermic Mice.International journal of fertility & sterility · 2025Article
- Preventing chemotherapy-induced ovarian damage through PI3K/AKT and Hippo pathway regulation.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Review
- Ovarian stimulation by promoting basal follicular growth.Reproductive biology and endocrinology : RB&E · 2025Review
- Mesenchymal stem cells: Guardians of women's health.Regenerative therapy · 2024Review
- The dual role of mesenchymal stem cells in apoptosis regulation.Cell death & disease · 2024Review
- Aberrantly High FBXO31 Impairs Oocyte Quality in Premature Ovarian Insufficiency.Aging and disease · 2024Article
- Administration of adipose-derived mesenchymal stem cell conditioned medium improves ovarian function in polycystic ovary syndrome rats: involvement of epigenetic modifiers system.Journal of ovarian research · 2023Article
- Potential Therapeutic Options for Premature Ovarian Insufficiency: Experimental and Clinical Evidence.Reproductive sciences (Thousand Oaks, Calif.) · 2023Review
- Multipotent fetal stem cells in reproductive biology research.Stem cell research & therapy · 2023Review
- The future of fertility preservation for women treated with chemotherapy.Reproduction & fertility · 2023Article
- Female Reproductive Aging and Oxidative Stress: Mesenchymal Stem Cell Conditioned Medium as a Promising Antioxidant.International journal of molecular sciences · 2023Review
- Neuroprotective effects of neural stem cells pretreated with neuregulin1β on PC12 cells exposed to oxygen-glucose deprivation/reoxygenation.Neural regeneration research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemotherapeutic agents are extensively used to treat malignancies. However, chemotherapy-induced ovarian damage and reduced fertility are severe side effects. Recently, stem cell transplantation has been reported to be an effective strategy for premature ovarian insufficiency (POI) treatment, but safety can still be an issue in stem cell-based therapy. Here, we show the protective effects of human umbilical cord mesenchymal stem cell-derived conditioned medium (hUCMSC-CM) on a cisplatin (Cs)-induced ovarian injury model. hUCMSC-CM can relieve Cs-induced depletion of follicles and preserve fertility. In addition, hUCMSC-CM can decrease apoptosis of oocytes and granulosa cells induced by Cs. RNA sequencing analysis reveals the differentially expressed genes of ovaries after Cs and hUCMSC-CM treatments, including genes involved in cell apoptosis. Furthermore, we show that the granulocyte colony-stimulating factor (G-CSF)/phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway plays an important role in protecting granulosa cells from Cs-induced apoptosis. Together, we confirm the protective effects of hUCMSC-CM on ovarian reserve and fertility in mice treated with Cs, highlighting the remarkable therapeutic effects of hUCMSC-CM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.